Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Evy
Evy Corbanie, Munich DE
| Patent application number | Description | Published |
|---|---|---|
| 20090232744 | Macrolide compositions having improved taste and stability - The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate; or mixtures thereof and (iii) a taste-masking agent different from said salt; wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%; (b) the molar ratio of said macrolide:said salt is in the range from about 1:0.5 to about 1:100; (c) the pH of the composition is in the range of about 3 to 9; and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability. | 09-17-2009 |
Evy Corbanie, Waregem BE
| Patent application number | Description | Published |
|---|---|---|
| 20090041852 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION - This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 μm and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation. | 02-12-2009 |
| 20110150940 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION - This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 μm and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation. | 06-23-2011 |
Evy De Leenheer, Sheffield GB
| Patent application number | Description | Published |
|---|---|---|
| 20110189208 | TB VACCINE - The invention relates to a vaccine useful in therapy and prevention of mycobacterial infections. | 08-04-2011 |
Evy Lundgren-Akerlund, Bjarred SE
| Patent application number | Description | Published |
|---|---|---|
| 20090185978 | Monoclonal antibody capable of binding integrin alpha 10 beta 1 - The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Methods and uses of said antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included. | 07-23-2009 |
| 20090232777 | Expansion and Differentiation of Mesenchymal Stem Cells - A cell culture system for expanding and differentiating mammalian mesenchymal stem cells to chondrocytes is provided. Said cell culture system comprises a subpopulation of isolated MSC selected for their expression of integrin alpha 10, as well as additives promoting expansion and differentiation to chondrocytes. Methods and uses of said expanded and differentiated cells with a chondrogen phenotype are also provided, as well as compositions comprising said expanded and differentiated chondrocyte cells. | 09-17-2009 |
| 20100055114 | USE OF INTEGRIN ALPHA 10 BINDING ANTIBODY TO MODULATE EXTRACELLULAR MATRIX (CARTILAGE) TURNOVER - The present invention relates to a novel use of alpha10, or a heterodimer thereof, for affecting cartilage extracellular matrix (ECM) turnover. Further, it relates to the use of a binding entity binding specifically to alpha10, or a heterodimer thereof, in the preparation of a medicament for treating a condition affecting ECM, such as rheumatoid arthritis and osteoarthritis. In particular, the invention relates to a method of treating an individual with a condition affecting ECM turnover, comprising administering to the individual an effective amount of a binding agent entity binding specifically to alpha10, or a heterodimer thereof. | 03-04-2010 |
| 20110033923 | MARKER FOR STEM CELLS AND ITS USE - A marker for mesenchymal stem cells (MSC) is provided, comprising an integrin alpha10 chain and/or an integrin alpha11 chain expressed on the cell surface of or intracellular in a MSC. The marker is used in methods for identification of mammalian MSC and in methods for isolation of MSC. Also included are isolated cellular populations of mammalian MSC and a cellular composition comprising the latter. Moreover, uses of said marker for isolation, modulation and identification of mammalian MSC are provided. | 02-10-2011 |
| 20110256061 | Binding agents to the Integrin Alpha-11 subunit, and uses thereof - The present invention relates to an antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, for use in medicine, wherein the antibody or antigen-binding fragment, variant, fusion or derivative thereof has binding specificity for an integrin α11 subunit, or a heterodimer thereof. In particular, the invention relates to the use of such antibodies or antigen-binding fragments, variants, fusions or derivatives thereof, in the treatment of inflammatory disorders such as arthritic diseases (e.g. rheumatoid arthritis and osteoarthritis). | 10-20-2011 |
Evy Lundgren-Äkerlund, Bjarred SE
| Patent application number | Description | Published |
|---|---|---|
| 20120034625 | Monoclonal Antibody Capable of Binding Integrin Alpha 10 Beta 1 - The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen and Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Methods and uses of said antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included. | 02-09-2012 |